Live In Play®
Updated: 20-Aug-24 06:01 ET
AZN:  AstraZeneca receives approval for Fasenra in China  (84.78)
  • AstraZeneca's Fasenra (benralizumab) has been approved in China by the country's National Medical Products Association (NMPA) for the maintenance treatment of patients 12 years of age and older with severe eosinophilic asthma (SEA).
  • The approval is based on results from the MIRACLE Phase III trial, which was conducted in China, South Korea and the Philippines.2 In the trial, Fasenra achieved a statistically significant and clinically meaningful 74% reduction (0.49 in the Fasenra group compared to 1.88 in the placebo group, rate ratio 0.26, p<0.0001) in the annualised asthma exacerbation rate (AAER) when added to standard of care in patients with SEA. Fasenra met all primary and key secondary endpoints in the trial, demonstrating improvements in lung function and asthma symptom control.
  • ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (DSNKY) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca
Cookies are essential for making our site work. By using our site, you consent to the use of these cookies. Read our cookie policy to learn more.